SARS-CoV-2 感染与移植相关生物学：我们处于什么位置？
SARS-Cov-2 infection in transplant-related biology: Where do we stand?
机构信息
Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China (mainland).
Physical Examination Center, Tianjin First Central Hospital, Tianjin, China (mainland).
出版信息
Ann Transplant. 2020 Dec 29;25:e924768. doi: 10.12659/AOT.924768.
Since December 2019, the novel coronavirus (SARS-CoV-2) emerged in Wuhan and rapidly spread throughout the world. There are nearly 3 951 905 confirmed cases of novel coronary pneumonia and more than 275 067 deaths worldwide, [JHU data-09/05/2020, https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6]. A great number of patients contracted SARS-Cov-2 pneumonia (COVID-19). SARS-CoV-2 invades human target cells through receptor angiotensin-converting enzyme II (ACE2), which are expressed in the lung, kidney, and ileum and mediate inflammatory responses and immune activities. High plasma levels of proinflammatory cytokines were detected in the infected patients. These factors may predispose transplant patients to high risk of poor outcomes. Therefore, transplant patients might be affected by this coronavirus infection and protection of allografts should receive special attention during this outbreak. In the present study we attempt to delineate the transplant-related biology of SARS-CoV-2 infection.
自 2019 年 12 月以来，新型冠状病毒（SARS-CoV-2）在武汉出现，并迅速在全球范围内传播。全球有近 3951905 例新型冠状肺炎确诊病例和超过 275067 例死亡病例，[JHU 数据-09/05/2020，https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6]。大量患者感染了 SARS-CoV-2 肺炎（COVID-19）。SARS-CoV-2 通过受体血管紧张素转化酶 II（ACE2）入侵人类靶细胞，ACE2 在肺、肾和回肠中表达，并介导炎症反应和免疫活性。在感染患者的血浆中检测到高水平的促炎细胞因子。这些因素可能使移植患者面临不良结局的高风险。因此，移植患者可能会受到这种冠状病毒感染的影响，在疫情期间，应该特别注意保护同种异体移植物。在本研究中，我们试图描绘 SARS-CoV-2 感染的与移植相关生物学。
Zotero 插件